ClinicalTrials.gg
Sign In
CompletedNCT04955535Updated Jul 8, 2021

Screening of Specific Genes for Pigmented Villous Nodular Synovitis

An observational study in Pigmented Villonodular Synovitis, sponsored by Peking University Third Hospital. Completed at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2021-07-08.

Sponsored by Peking University Third Hospital · Observational

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
60
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This study retrospectively analyzed the history of present illness of PVNS patients in our hospital. The enrolled patients were followed up by telephone to follow up their postoperative recovery and living conditions. Take the patient's pathological specimens for immunohistochemical testing, evaluate the relationship between the expression of different molecular targets, clinical manifestations and patient prognosis, and explore new molecular targets related to disease diagnosis and treatment.

Read the detailed description

This study retrospectively analyzed the symptoms, time of onset, injury history, laboratory examinations, imaging examinations, and intraoperative conditions of PVNS patients in our hospital. The enrolled patients were followed up by telephone to follow up their postoperative recovery and living conditions (VAS score, SF-36 score). Take the patient's pathological specimens for immunohistochemical testing, evaluate the relationship between the expression of different molecular targets, clinical manifestations and patient prognosis, and explore new molecular targets related to disease diagnosis and treatment.

02

Conditions studied

  • Pigmented Villonodular Synovitis
03

In context

Synovitis, Pigmented Villonodular

20 studies on the registry are indexed under Synovitis, Pigmented Villonodular; 2 are open to participants now.

Browse Synovitis, Pigmented Villonodular studies →

Lead sponsor

Peking University Third Hospital is the lead sponsor of 752 studies on the registry; 273 are open to participants now.

Browse Peking University Third Hospital studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with "pigmented villonodular synovitis" and "giant cell tumor of tendon sheath"

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Clinical diagnosis of pigmented villonodular synovitis.
  2. Clinical diagnosis of giant cell tumor of tendon sheath

Exclusion criteria

Exclusion Criteria:

  1. No surgical treatment.
  2. There were no pathological specimens during the operation.
  3. The age of the patient is less than 18 years old or more than 60 years old.
  4. The operation record shows nodular type.
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
60 participants (actual)
Patient registry
No

Interventions

  • ProcedureArthroscopic synovectomy

    Arthroscopic synovectomy

06

What researchers measure

Primary outcomes

  1. Difference of scale score between immunohistochemistry positive group and negative group

    Difference of Visual Analog Score for pain between CSF-1 immunohistochemistry positive group and negative group

    Time frame: One week after surgery

  2. Difference of Visual Analog Score for pain between TNF-α immunohistochemistry positive group and negative group

    Difference of Visual Analog Score for pain between TNF-α immunohistochemistry positive group and negative group

    Time frame: One week after surgery

  3. Difference of Visual Analog Score for pain between IL-1B immunohistochemistry positive group and negative group

    Difference of Visual Analog Score for pain between IL-1B immunohistochemistry positive group and negative group

    Time frame: One week after surgery

  4. Difference of SF-36 score between CSF-1 immunohistochemistry positive group and negative group

    Difference of SF-36 score between CSF-1 immunohistochemistry positive group and negative group

    Time frame: One week after surgery

  5. Difference of SF-36 score between TNF-α immunohistochemistry positive group and negative group

    Difference of SF-36 score between TNF-α immunohistochemistry positive group and negative group

    Time frame: One week after surgery

  6. Difference of SF-36 score between IL-1B immunohistochemistry positive group and negative group

    Difference of SF-36 score between IL-1B immunohistochemistry positive group and negative group

    Time frame: One week after surgery

Secondary outcomes

  1. Correlation between basic demographic characteristics and scale scores

    Correlation between age, gender and scale score

    Time frame: One week after surgery

07

Study locations

1 site
  • Institute of Sports Medicine, Peking University Third Hospital, Beijing Key Laboratory of Sports Injuries， Beijing, China
    Beijing, Beijing 100191, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Dec 2020, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2021
First posted
Jul 8, 2021
StartActual
Aug 3, 2020
Primary completionActual
Dec 27, 2020
CompletionActual
Dec 27, 2020
Last update
Jul 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04955535
Lead sponsor
Peking University Third Hospital
Responsible party
Sponsor
First posted
Jul 8, 2021
Start date
Aug 3, 2020
Primary completion
Dec 27, 2020
Completion
Dec 27, 2020
Last update
Jul 8, 2021

Study contacts

Yingfang Ao, Prof.
study chair · Peking Yniversity Third Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Synovitis, Pigmented Villonodular →

Other studies from this sponsor

Peking University Third Hospital →

Start the discussion